Unlocking the promise of mRNA therapeutics

• Published in: Nature biotechnology Vol. 40; no. 11; pp. 1586 - 1600
• Main Authors: Rohner, Eduarde, Yang, Ran, Foo, Kylie S, Goedel, Alexander, Chien, Kenneth R
• Format: Journal Article
• Language: English
• Published: United States 01.11.2022
• Subjects: COVID-19 - prevention & control; COVID-19 Vaccines; Genetic Vectors; Humans; Medicin och hälsovetenskap; RNA, Messenger - genetics; RNA, Messenger - therapeutic use; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - metabolism
• ISSN: 1087-0156; 1546-1696; 1546-1696
• DOI: 10.1038/s41587-022-01491-z

The extraordinary success of mRNA vaccines against coronavirus disease 2019 (COVID-19) has renewed interest in mRNA as a means of delivering therapeutic proteins. Early clinical trials of mRNA therapeutics include studies of paracrine vascular endothelial growth factor (VEGF) mRNA for heart failure and of CRISPR-Cas9 mRNA for a congenital liver-specific storage disease. However, a series of challenges remains to be addressed before mRNA can be established as a general therapeutic modality with broad relevance to both rare and common diseases. An array of new technologies is being developed to surmount these challenges, including approaches to optimize mRNA cargos, lipid carriers with inherent tissue tropism and in vivo percutaneous delivery systems. The judicious integration of these advances may unlock the promise of biologically targeted mRNA therapeutics, beyond vaccines and other immunostimulatory agents, for the treatment of diverse clinical indications.